Latest Breaking News On - Immix biopharma inc nasdaq - Page 1 : vimarsana.com

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

LOS ANGELES, July 25, 2023 Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. , today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for.

United statesPolina stepenskyLos angelesAlex loboInternational myeloma working groupImmix biopharma inc nasdaqDepartment of bone marrow transplantationInternational myeloma society annual meetingExchange commissionNexcella incCompany contactImmix biopharma incHadassah medical organizationGlobenewswire incMyeloma society annual meetingBone marrow transplantation

Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAlex loboPolina stepenskyLos angelesNexcella incExchange commissionImmix biopharma incImmix biopharma inc nasdaqInternational myeloma society annual meetingInternational myeloma working groupCompany contactMyeloma clinical data abstract acceptedInternational myeloma society annualHadassah medical organizationBone marrow transplantationMultiple myeloma

Immix Biopharma Subsidiary Nexcella Announces NXC-201

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023.

United statesAlex loboLos angelesPolina stepenskyImmix biopharma incNexcella incInternational myeloma society annual meetingImmix biopharma inc nasdaqInternational myeloma working groupExchange commissionImmix biopharmaHadassah medical organizationBone marrow transplantationMultiple myelomaUniform response criteriaTissue specific therapeutics

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract

LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical

United statesLos angelesAlex loboPolina stepenskyInternational myeloma working groupImmix biopharma incInternational myeloma society annual meetingExchange commissionCompany contactImmix biopharma inc nasdaqNexcella incImmix biopharmaHadassah medical organizationBone marrow transplantationMultiple myelomaUniform response criteria

Nexcella Appoints Edward J Borkowski, former Chief

Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry,.

Carl icahnEdwardj borkowskiLos angelesGabriel morrisAdvanz pharmaIlya rachmanAlex loboRutgers universityCompany board of directorsBecton dickinsonExchange commissionAllegheny collegeNexcella incImmix biopharma incAmerigen pharmaceuticalsTrustee of allegheny college